235 related articles for article (PubMed ID: 26109367)
1. CEA in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
Sagi-Dain L; Lavie O; Auslander R; Sagi S
Int J Biol Markers; 2015 Nov; 30(4):e394-400. PubMed ID: 26109367
[TBL] [Abstract][Full Text] [Related]
2. CA 19-9 in evaluation of adnexal mass: retrospective cohort analysis and review of the literature.
Sagi-Dain L; Lavie O; Auslander R; Sagi S
Int J Biol Markers; 2015 Jul; 30(3):e333-40. PubMed ID: 25704505
[TBL] [Abstract][Full Text] [Related]
3. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.
Moro F; Pasciuto T; Djokovic D; Di Legge A; Granato V; Moruzzi MC; Mancari R; Zannoni GF; Fischerova D; Franchi D; Scambia G; Testa AC
Ultrasound Obstet Gynecol; 2019 Jan; 53(1):116-123. PubMed ID: 29978587
[TBL] [Abstract][Full Text] [Related]
4. Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass: Retrospective Cohort Study and Review of the Literature.
Sagi-Dain L; Lavie O; Auslander R; Sagi S
Am J Clin Oncol; 2018 Sep; 41(9):838-844. PubMed ID: 28338481
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the importance of the serum levels of CA-125, CA15-3, CA-19-9, carcinoembryonic antigen and alpha fetoprotein for distinguishing benign and malignant adnexal masses and contribution of different test combinations to diagnostic accuracy.
Bozkurt M; Yumru AE; Aral I
Eur J Gynaecol Oncol; 2013; 34(6):540-4. PubMed ID: 24601047
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of the preoperative platelet count in the diagnosis of adnexal tumors.
Watrowski R; Heinze G; Jäger C; Forster J; Zeillinger R
Tumour Biol; 2016 Sep; 37(9):12079-12087. PubMed ID: 27207344
[TBL] [Abstract][Full Text] [Related]
7. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age.
Kondalsamy-Chennakesavan S; Hackethal A; Bowtell D; ; Obermair A
Gynecol Oncol; 2013 Jun; 129(3):467-71. PubMed ID: 23500084
[TBL] [Abstract][Full Text] [Related]
8. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.
Terlikowska KM; Dobrzycka B; Witkowska AM; Mackowiak-Matejczyk B; Sledziewski TK; Kinalski M; Terlikowski SJ
J Ovarian Res; 2016 Jul; 9(1):43. PubMed ID: 27436085
[TBL] [Abstract][Full Text] [Related]
9. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay.
Bristow RE; Smith A; Zhang Z; Chan DW; Crutcher G; Fung ET; Munroe DG
Gynecol Oncol; 2013 Feb; 128(2):252-9. PubMed ID: 23178277
[TBL] [Abstract][Full Text] [Related]
10. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
[TBL] [Abstract][Full Text] [Related]
11. [Comparative evaluation of diagnostic significance of carbohydrate antigen CA125 and cancer-embryonal antigen in ovarian cancer].
Lapchenkov VI; Dudarev AL; Vinokurov VL; Iurkova LE; Barbanel EIu
Vestn Rentgenol Radiol; 1993; (5):30-1. PubMed ID: 7801580
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy and cost-effectiveness of different strategies to triage women with adnexal masses: a prospective study.
Piovano E; Cavallero C; Fuso L; Viora E; Ferrero A; Gregori G; Grillo C; Macchi C; Mengozzi G; Mitidieri M; Pagano E; Zola P
Ultrasound Obstet Gynecol; 2017 Sep; 50(3):395-403. PubMed ID: 27706929
[TBL] [Abstract][Full Text] [Related]
14. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
15. The Diagnostic Value of Transvaginal Sonograph (TVS), Color Doppler, and Serum Tumor Marker CA125, CEA, and AFP in Ovarian Cancer.
Zhang F; Zhang ZL
Cell Biochem Biophys; 2015 Jun; 72(2):353-7. PubMed ID: 25582421
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the diagnostic value of using serum CA125 and GI-RADS system in the evaluation of adnexal masses.
Zheng H; Tie Y; Wang X; Yang Y; Wei X; Zhao X
Medicine (Baltimore); 2019 Feb; 98(7):e14577. PubMed ID: 30762809
[TBL] [Abstract][Full Text] [Related]
17. CA72-4 combined with CEA, CA125 and CAl9-9 improves the sensitivity for the early diagnosis of gastric cancer.
Yang AP; Liu J; Lei HY; Zhang QW; Zhao L; Yang GH
Clin Chim Acta; 2014 Nov; 437():183-6. PubMed ID: 25086284
[TBL] [Abstract][Full Text] [Related]
18. Preoperative measurement of serum C-reactive protein: is it useful in the differential diagnosis of adnexal masses?
Yoshida A; Derchain SF; Pitta DR; Crozatti N; Andrade LALA; da Silva RF; Sarian LO
Int J Biol Markers; 2017 Mar; 32(1):e83-e89. PubMed ID: 27516000
[TBL] [Abstract][Full Text] [Related]
19. Simple laboratory score improves the preoperative diagnosis of adnexal mass.
Watrowski R; Zeillinger R
Tumour Biol; 2016 Apr; 37(4):4343-9. PubMed ID: 26499778
[TBL] [Abstract][Full Text] [Related]
20. Improved Detection Rate of Ovarian Cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting.
Manegold-Brauer G; Buechel J; Knipprath-Mészaros A; Schoetzau A; Hacker NF; Tercanli S; Lapaire O; Heinzelmann-Schwarz V
Int J Gynecol Cancer; 2016 Jul; 26(6):1062-9. PubMed ID: 27177281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
